Relevium’s Biocannabix Receives City Approval for Medical Cannabis Facility
Momentum Public Relations
Press Release: July 19 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) and (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that the company’s wholly owned subsidiary Biocannabix Health Corporation (“BCX”) has received an approval letter from the City of Ville St-Laurent (VSL), located in Montréal, Québec for the Company’s 93,000 SQ. FT. cultivation and fully integrated processing facility under the Access to Cannabis for Medical Purposes Regulations (ACMPR).
Aurelio Useche, CEO of Relevium stated: “The approval letter from the City of Ville Saint-Laurent constitutes an important milestone for the Company as it provides the project with municipal support and considerably de-risks the process.” Mr. Useche continued: “To our knowledge the Biocannabix facility will be the most central ACMPR licensed producer in the Greater Montreal area, a city that is the second largest population center in Canada and with its strategic location, which is situated 20 minutes from the downtown core and adjacent to the TransCanada highway. This will provide the company with an important competitive advantage.”
Now that the approval letter from the city of Saint-Laurent has been granted, the Company will now focus on finalizing the lease agreement for the facility. The Company intends to have the lease agreement finalized within the next 30 days. The Company will continue to work with its consultants, PipeDreemz Inc. on the construction design, business plan and cultivation parameters for the facility and expects to provide an update on progress by late summer.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or brands with a focus on e-commerce in the growing health and wellness sector. The Company, through its wholly-owned subsidiary, Biocannabix Health Corporation, is also incorporating cannabinoids into its nutraceutical strategy and provide its retail customers access to the health benefits of cannabis through its formulations and established brands.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Starts Production of Two Exclusive Formulations With Patented Provinal® Omega 7
Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) and (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has put into production 920,000 soft-gels each of its Cardio-Metabolic Syndrome and Dry-Eye Syndrome formulations containing Provinal® Omega 7.
Highlights
- Relevium puts into production 920,000 soft gels using Provinal® is a patented ultra-purified Omega 7 fatty acid blend
- CardiaPro with Provinal® is shown to support cardio metabolic health by reducing insulin resistance, hepatic fat accumulation and acute and chronic inflammation
- VisionPro with Provinal® is also shown to improve the quality of tears and with its exclusive formulation, supports complete eye health
- First formulations with North American exclusivity for online sales through Amazon, Walmart and Native Website.
On December 6, 2017 the Company announced an exclusivity agreement with Tersus Life Sciences to formulate and distribute exclusive products with Provinal® Omega 7. The Company has put into production its first two formulations aimed at servicing two critical markets, Heart and Eye Health.
The two formulations will be marketed through BioGanix® Platinum and Bioganix® Gold labels throughout its online presence in its Native Website, Social Media, Amazon and Walmart and they are expected to be available for sale in September of this year.
Aurelio Useche CEO Stated: “The start of the production of these unique products represent a critical milestone for Relevium and its Bioganix® brand” Mr. Useche stated further: “We have been positively overwhelmed with the professionalism and excellence demonstrated by the team of scientists and formulators at Tersus Life Sciences and we are proud to be able to provide a superior and unique formulation with their patented Provinal® Omega 7 fish oil”.
About Provinal® Omega 7
Provinal® Omega 7 is a novel, patented and clinically-substantiated monounsaturated fatty-acid ingredient targeting the prevention and reversal of dyslipidemia, and cardio-metabolic disorders. Provinal® Omega 7 is a naturally-occurring highly purified monounsaturated fatty acid. Preclinical and clinical evidence has demonstrated a broad range of benefits bridging the treatment gap in highly prevalent disorders with special emphasis on lipid management.
Omega 7 (purified palmitoleic acid) oil of palmitate can potentially help in the fight against diabetes, metabolic syndrome, and atherosclerosis. In this 4-minute video, Dr. Michael F. Roizen, frequent contributor on the Dr. Oz show and Chairman of the Wellness Institute of The Cleveland Clinic, explores the beneficial effects of Provinal® on the management of atherosclerosis, its causes and consequences: heart disease, stroke, memory loss, impotence, and wrinkling.
Purified Omega 7 has been shown to decrease insulin resistance, decrease hepatic fat accumulation, and decrease acute and chronic inflammation – with no known side effects. More information can be found on the Tersus Life Sciences webpage at tersuslifesciences.com
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Selects 93,000 Sq. Ft Organic Cultivation Facility in Quebec
Momentum Public Relations
Press Release: June 4 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that, through its wholly-owned subsidiary Biocannabix (“BCX”), it has selected a 93,000 square foot facility in Montreal, Quebec with the objective of cultivating premium organic cannabis.
With the assistance of PipeDreemz Inc., Relevium has conducted initial assessment on the facility, a 93,000 Sq. Ft industrial building located adjacent to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montreal. The building has been selected as a desirable location with a low risk profile for the application submission to Health Canada for an ACMPR cultivation license. Biocannabix will be leveraging the vast experience of lead consultant George Routhier and his company PipeDreemz Inc., a company with a remarkable 100% rate of success with ACMPR licensing from Health Canada.
Company Strategy
The strategy for the Company is to cultivate high quality organic strains for use in exclusive, high-end consumer packaged goods primarily for health and wellness. The Company will not compete on large scale supply, but rather plans to focus on custom niche and organic products with established partnerships for processing and ongoing research in cannabis derivatives.
The Company intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 Sq. Ft of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
Aurelio Useche, CEO of Relevium stated: “The strategy of Biocannabix will not be catered around being the lowest cost producer, but rather on being a premium and custom producer focused on consumer packaged goods to be sold through Relevium’s current and new brands.” Mr. Useche stated further: “The value in the supply chain will be in developing trusted, unique, ultra-premium product for luxurious brands.”
About PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Revenue of $3.2M for the Nine-Month Period Ended March 31, 2018
Momentum Public Relations
Press Release: May 30 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”) is pleased to announce its financial and operating results for the three and nine months’ period ended March 31, 2018.
Highlights
- Nine-month sales totalled $3,157,644 including Q3 sales of $1,063,176 recorded by Bioganix®
- Nine-month gross profit of $1,806,515 (57%), including Q2 gross profit of $575,495 (56%)
- In this reporting period, the Company:
- Initiated a market test for the eventual launch of a complete Aloe Vera based health support products and cosmetics
- Revealed a new brand architecture for Bioganix®
- Conducted the initial joint-launch of Planet Hemp with HEMPCO
- Established its presence for the European marketplace in partnership with Amazon
- The Company increased product offerings by 17% to 38 products with further plans to expand to over 50 products in 2018
Results from Operations
During the nine-month period ended March 31, 2018, the Bioganix brand generated $3,157,644 in sales revenues with a gross profit of $1,806,515. A gross margin of 57% continues to remain stable and adjusted EBITDA for the brand remains positive at 25%. On a consolidated basis, the Company reported an increase in expenses in three key areas:
- Selling and Marketing Expenses: The reporting period was marked by a period of preparation for market expansion, which included increased expenses relating to initiatives to build brand equity, expand geographically, launch of new products and build the operating team. The investments included brand repositioning and branding services, promotions and new product launches, increased digital marketing campaigns and other value-added services. The total marketing expense for the nine-month was reported at $1,252,668 with $313,167 allocated to market expansion, branding and product launch initiatives.
- Interest and Accretion Expenses: The Company reported a total of $612,040 ($348,422 of interest and $263,618 of accretion) in the nine-month reporting period for servicing the long-term convertible debt currently on the balance sheet.
- Share-based compensation: The Company reported $554,110 non-cash share-based compensation, reflecting stock options issued to directors, consultants and management in the reporting nine-month period.
These three key areas represent $2,418,818 or 67% of all the Company’s operating expenses for the nine-month reporting period. The Company reported net and comprehensive losses of $1,787,985 ($566,070 in 2017) and Adjusted Earnings Before Interest, Taxes and Amortization totaling $384,151 in the same period.
Aurelio Useche, President and CEO of Relevium stated: “We have increased our marketing and sales spend significantly to successfully launch a new brand, new products and to expand into new markets as previously announced.” Mr. Useche stated further: “Revenues from the original Bioganix product line remain as expected and believe that the additional investments will bear fruit once our presence in Amazon UK and Walmart.com is strong and the new products have taken hold within our customer base.”
For more information, the Company’s previous filings may be reviewed by visiting www.sedar.com and also our website www.releviumtechnologies.com.
Adjusted EBITDA and Non-IFRS Financial Measures
The Management Discussion and Analysis for the same period includes certain measures which are not defined terms in accordance with IFRS such as Adjusted EBITDA. The term “Adjusted EBITDA” refers to net income or net loss after adjusting for interest, taxes, depreciation and costs relating to acquisitions and their integration.
The Company believes that Adjusted EBITDA is useful, supplemental information as it provides an indication of the results generated by the company’s main business activities prior to taking into consideration how those activities are financed and taxed and prior to taking into consideration depreciation and particularly the costs of integration of acquisitions.
Adjusted EBITDA is also a key measure used by the Company’s management and its Board of Directors to understand and evaluate the Company’s operating performance, to prepare annual budgets, and to help develop operating plans. Adjusted EBITDA is not a measure of performance under IFRS and should not be considered in isolation or as a substitute for net and comprehensive income or loss prepared in accordance with IFRS or as a measure of operating performance or profitability.
Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
See “Adjusted EBITDA and Non-IFRS Financial Measures”
- Published in Relevium Technologies
Relevium Appoints New CFO to Drive Performance
Momentum Public Relations
Press Release: May 25 2018
Relevium TechnologiesInc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has appointed Mr. Faycal Salek CPA, CA as the Chief Financial Officer of the Company effective immediately.
Mr. Salek is a graduate in business administration from l’École des Hautes Études Commerciales (“HEC”) in Montreal and obtained a specialized degree from the HEC in public accounting in 2002, becoming a chartered accountant in 2004 and is a member of l’Ordre des Comptables Agréés du Québec (CPA, CA). Mr. Salek has acted as the CFO to several private and publicly traded corporations. Mr. Salek worked as for CPA Quebec as a Professional Inspector and was Vice-President Finance at Hitlab Inc., a music technology and social media corporation. Mr. Salek also worked at Petrie Raymond, Chartered Accountants LLP, as the Manager responsible for the audit of several public companies in the mining and technology fields.
Aurelio Useche, CEO of Relevium stated: “We would like to thank Mr. Waks for his years of services and welcome Mr. Salek to the Team.” Mr. Useche continued: “Mr. Salek has the ideal attributes and complimentary financial acumen to add immediate value to Relevium. Mr. Salek has begun streamlining the financial reporting function and we look forward to his active participation in the strategic planning process, performance optimization and modeling for mergers and acquisitions.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Engages PipeDreemz as Lead ACMPR Consultant for Biocannabix
Momentum Public Relations
Press Release: May 17 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has engaged PipeDreemz as lead consultant (the “Consultant”) for the Biocannabix Health Corp (“BHC”) ACMPR applications to Health Canada to obtain the necessary licenses. Biocannabix will focus on organic products and on the development of specialty genetic strains targeting primarily cannabidiol (CBD) and cannabigerol (CBG) for use in medical applications as well as consumer packaged goods.
Highlights
- Industry veteran Georges Routhier and PipeDreemz have been providing advisory services to a number of successful Licensees
- Instrumental in designing the H2 Biopharma facility in Lachute, Qc., acquired by Aurora Cannabis
- The PipeDreemz team holds advanced degrees in science, engineering, business, agriculture, horticulture and plant sciences
- As at January 1, 2018 PipeDreemz had 23 highly advanced facilities under construction across Canada
- ACMPR license application submission forecasted for Summer 2018
Aurelio Useche, CEO of Relevium stated: “Since the creation of Biocannabix Health Corp, a wholly-owned subsidiary of Relevium, we have interviewed a multitude of cannabis consultants, key industry suppliers and advisors with a focus on the Quebec market.” Mr. Useche continued: “We are extremely pleased to partner with George Routhier and the team at PipeDreemz who were highly recommended by industry insiders. George is a veteran in the industry, has a proven track record and shared values with Relevium in terms of the evolution of the cannabis business both in Canada and around the world.”
The Company will begin working immediately with the PipeDreemz and its advisors in the evaluation of selected locations in and around Montreal, Quebec, where the company will host its operations. All facets of the operations, from HVAC to security, genetics and micropropagation, to distribution and branding will be taken into consideration in order to ensure aligned strategic fit and the best possible long-term ROI for the company and its shareholders.
The Company anticipates that the application will be deposited to Health Canada before July 31, 2018.
More about PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
PipeDreemz cemented its position as an expert in the cannabis field following the sale of a PipeDreemz designed state-of-the-art, 49,000 square foot cannabis production facility to Aurora Cannabis Inc. H2 Biopharma retained PipeDreemz for start to finish services including design and oversight on construction of the facility, located in Lachute, Quebec. Aurora Cannabis Inc. acquired the PipeDreemz designed facility from H2 Biopharma in November 2017.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Launches Bioganix® on Walmart.com
Momentum Public Relations
Press Release: May 3 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that it has received approval to sell its biggest mover Bioganix® products on Walmart.com.
Highlights
- New and diverse revenue channel with over 400M monthly visitors
- Onboarding and approval to Walmart.com is complete
- Sales testing of Bioganix® products is currently online
- Bioganix® will launch best selling SKUs and customize a new offering for a new demographic
- Opens a new sales vertical and mitigates channel risk
Walmart.com will provide Relevium with access to 400M new visitors per month with a diverse customer demographic and profile. According to CBS MoneyWatch, Walmart.com shoppers are primarily young women and nearly half have families with kids and a diverse ethnic profile. Amazon and Walmart demographics are complementary thereby mitigating channel risk for the Bioganix® brand.
Aurelio Useche, CEO of Relevium stated: “The addition of the Walmart.com platform to the existing Amazon.com sales channel gives Bioganix® a new and diverse audience and should prove to be accretive to revenues going forward.” Mr. Useche continued: “Diversifying our sales channels also de-risks the reliance on individual marketplaces and allows us to reach new customers across the USA, Europe and Asia. This is a major step for the Company and our expectations are high.”
Abis Hussain, SMO of Relevium, stated: “The Operations Team has concluded that the audience and the competition on Walmart.com is very different than those in Amazon.com and should reflect nicely on the bottom line for the Company. As an added bonus, Walmart.com will be key to the introduction of full spectrum hemp oil products, which will prove to be extremely valuable going forward as we prepare to launch products related to the space.”
Bioganix® products have been available on the Walmart.com platform, on a test-basis, for sale and delivery in the United States of America as of May 1, 2018. Initially, the Company will be offering five (5) to eight (8) of its best-selling products on the platform and then evaluate which products will subsequently be made available.
Relevium has the intention of selling products from its current catalogue as well as new products that will be launched in 2018. New products will be centered around major themes in the health and wellness markets including weight management, sports performance, ketogenic diets and general well being offered through hemp-derived products.
Bioganix® products will now be widely available in the USA through Bioganix.com, Amazon.com and Walmart.com and imminently in the United Kingdom through Amazon.co.uk.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Agreement with Neptune Wellness for MaxSimil®
Momentum Public Relations
Press Release: April 30, 2019
Relevium Technologies Inc. (TSX.V:RLV), (OTCQB:RLLVF) and (Frankfurt:6BX) (the“Company” or “Relevium”), is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
Highlights
- MaxSimil® is a technology that enhances the absorption of lipid and lipid-soluble ingredients in the production of nutraceuticals
- The agreement includes product development, supply and commercialization for Canada and USA
- Initial 2-year term
- Development of two (2) products in year one and an additional six (6) within year two
- The agreement includes Research and Development contribution by Relevium in the form of a 2.5% royalty on net sales payable to Neptune quarterly
Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”
Francois-Karl Brouillette, Neptune’s VP, Science and Innovation stated:” Relevium’s business and product development strategies will be great accelerators to Neptune’s own MaxSimil® nutraceutical development program. Free of any unwanted excipients and mimicking our natural biological system, MaxSimil technology is an efficient nutraceutical-type delivery system that is perfectly compatible with today’s dietary supplement industry.” Mr. Brouillette added: “I strongly believe that this exciting new partnership will help us further unlock this patented technology’s full potential while extending its reach to a broader consumer base.”
About MaxSimil®
MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as plant and fish derived oils.
About Neptune Wellness Solutions
Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. The Company’s head office is located in Laval, Quebec.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses and entrepreneurial brands in the growing health and wellness sector. The Company creates value by building brand equity, organic product offering and geographic expansion. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook, Follow us on Twitter
and Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Creates Cannabis Brands for North-American Market
Momentum Public Relations
Press Release: April 26
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of its two first cannabis brands, LeefyLyfe and Biocannabix offering cannabis products in the North-American and European markets. LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health Corporation (the “Subsidiary” or “BHC”).
Highlights
- Biocannabix® will target the Canadian market pursuant to ACMPR regulations
- LeefyLyfe® will target CBD sales outside of Canada in full compliance with local legal and regulatory framework
- All resources being pooled to fast track the company’s positioning in the cannabis space
Aurelio Useche, CEO of Relevium stated: “We believe the organizations that build credible, trusted and recognizable brands in the CBD market will be the winners in this already fragmented space. At RLV, we are leveraging our current branding and online abilities in combination with all the resources at our disposal internally and externally to position the Company in the consumer products cannabis space.” Mr. Useche continued: “From formulation to branding and e-retail, we will be able to monetize CBD and CBG based consumer products outside of the Canadian market while the application for an ACMPR license for Canada is being worked on. We believe that this approach provides the best balance of short and mid-term ROI and an ideal risk ratio.”
Biocannabix
Relevium will be building the Biocannabix® brand in for the Canadian market and focus the brand architecture towards the medical and health markets. The Company has secured http://biocannabix.com/as the domain for the brand.
In order to gain access to the cannabis for medical purposes market and obtain the necessary licenses from Health Canada, including the ACMPR license, the Company has begun the process of evaluating locations in Quebec that could accommodate the operation. The Company has studied industry peers and believes that with the amount of data available it will be able to act swiftly and in a very cost-effective manner.
LeefyLyfe
Relevium will be building LeefyLyfe® as an elevated and trusted brand for the health-conscious consumer outside of Canada, with a focus on full spectrum hemp, CBD and CBG formulations aimed for lifestyle, health and wellness. The product offering targetsapplications ranging from pain relief and anti-inflammation to anxiety and sports performance. The Company has secured http://leefylyfe.com/ as the domain for the brand.
Relevium has already shortlisted production partners that would be able to meet stringent legal and compliance guidelines. All products being contemplated for the LeefyLyfe® brand will be derived from American grown, organic and non-genetically modified hemp.
The Company projects sales for LeefyLyfe® to commence in Summer in full compliance with rules, regulations and laws at the State and Federal levels.
Building a Brand Portfolio
In full alignment with the company’s business strategy, management is engaged in a process to secure branding licensing agreements and endorsement opportunities tailored for different consumer segments in this market. As opportunities arise, they will be subject to focus group and SWOT analysis in order to evaluate a proper risk/reward for the Company. The Company anticipates having a high-end premium or luxury brand offering in the spring or summer depending on a variety of factors.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
Momentum Public Relations
Press Release: April 19 2018
Relevium TechnologiesInc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of Biocannabix Health Corporation (the “Subsidiary” or “BHC”), a Canadian wholly owned subsidiary structured to lead the development of the legal cannabis derivatives business for RLV. The Company projects to complete its ACMPR application for the Canadian marketplace within the current fiscal quarter and has begun to assemble its legal and regulatory team of experts within targeted jurisdictions.
Highlights
- Biocannabix Health Corporation to lead the Company’s legal cannabis initiatives
- Focus on developing a portfolio of high end consumer brands for North America
- Prepare for a global online marketplace for jurisdictions with a legal context
- Subsidiary anticipates applying for the necessary ACMPR licenses from Health Canada
- Initial commercial focus will be on industrial hemp derivatives such as CBG and CBD
As a Canadian company, Relevium will initially target the legal cannabinoids markets in North-America and develop medical, lifestyle and luxury consumer products aimed at supporting overall health and wellness. The Company’s newly created subsidiary is expected to begin the process of obtaining access to cannabis for medical purposes through the filing of an application for the appropriate licences from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The primary purpose of the application will be to enable the Company, through Biocannabix, to secure the appropriate legal authorizations to be able to distribute and sell medical cannabis products in Canada and service other jurisdictions in the export market.
Aurelio Useche, CEO of Relevium stated: “Our core business is health and wellness and the legal Cannabis derivative business is growing exponentially in our niche. In the US, relaxing regulations and a fragmented market place represent a true opportunity to build elevated and trusted cannabinoid derivative consumer brands”. Mr. Useche continued: “In the industrial hemp derivatives space there is rapid proliferation of cannabinoids-based products like CBG and CBD. The challenge, however, is Branding, Quality and Customer Experience, all areas that RLV intends to leverage through its channel expertise.”
The Company’s strategic direction is very much in-line with its core business, which includes the creation of a portfolio of online, direct to consumer retail brands in Health and Wellness, both organically, through licensing agreements and via acquisitions.
The Company understands this is a fast-evolving regulatory environment. In order ensure the adoption of a full legal and compliant framework, the Company is assembling a team of legal and business experts from the space.
About the Market
According to a report from Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is expected to reach $63.5 billion in 2024, growing at a compound annual growth rate of 21.1 percent during the forecast years. North America accounts for over 49% of the market, with the U.S. being the single largest market.
A Major segment of the legal cannabis industry is the hemp-derived cannabidiol (CBD) market. According to a report by Forbes, Brightfield Group projects that Hemp-derived cannabidiol (CBD) will be a billion-dollar market in just three years. CBD products do not have any psychotropic effects and are usually used for medical purposes. Brightfield’s data estimates that hemp CBD sales have already hit $170 million in 2016 and at a 55% compound annual growth rate over the next five years the market will cross the billion-dollar mark. According to Statista, it is estimated that in the year 2020 CBD consumer sales will total around 1.15 billion U.S. dollars. Brightfield determined that 64.5% of the sales come through the online channel followed by 17.8% from physical points of sale.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies